Thiazolidinedione reduces mortality, adverse events in T2D patients with AKD

Treatment with thiazolidinedione (TZD) results in a significant decrease in mortality, cardiovascular events, and kidney-related adverse events among type 2 diabetes (T2D) patients with acute kidney disease (AKD), a recent study has shown.

A total of 263,101 patients with AKD and T2D were enrolled in this study. Of these, 2,723 (1.03 percent) used TZD during the AKD period. After propensity score matching (PSM), 2,555 participants (mean age 64.0 years, 53.82 percent male) were included in the analysis.

Patients treated with TZD demonstrated reduced risks for all-cause mortality (hazard ratio [HR], 0.68, 95 percent confidence interval [CI], 0.57–0.81), major adverse cardiovascular events (MACE; HR, 0.68, 95 percent CI, 0.58–0.80), and major adverse kidney events (MAKE; HR, 0.75, 95 percent CI, 0.66–0.86) over a median follow-up of 1.5 years.

“These findings suggest a potential benefit of TZD usage for managing cardiovascular events in T2DM patients with AKD,” the investigators said. 

This study utilized the TriNetX platform before 30 September 2022 for TZD use in patients with T2D within 90 days of an AKD diagnosis. The investigators assessed the following clinical endpoints: all-cause mortality, MACE, and MAKE. They calculated HRs and 95 percent CIs with 1:1 ratio PSM.

“Patients with diabetes are prone to acute kidney injury with the potential transition to chronic kidney disease,” the investigators said. “Few studies have investigated the role of TZD in these patients under AKD phase.”